Background: Preterm birth is a significant cause of perinatal morbidity and mortality and that becomes a major challenge in perinatal health care. Various pharmacological agents that inhibit uterine contractions are used in clinical practice to prevent preterm delivery. The maternal and fetal side-effect profiles of tocolytic agents are becoming an important consideration in selecting the drug of choice. Nifedipine, a dihydropyridine calcium entry blocker, is an effective tocolytic agent with low toxicity and teratogenicity, while carrying potential maternal as well as fetal vascular side effects due to its action on vascular smooth muscle. This study was performed to asses nifedipine use as tocolytic agent in preventing preterm birth, and assesing maternal as well as fetal vascular side effects.Methods: This experimental study with one-group pretest-posttest design was performed in 30 pregnant women undergoing nifedipine as tocolytic. Doppler assessment of uterine, umbilical and fetal middle cerebral arteries, ductus venosus, and cerebroplacental ratio was performed before and 48 hours after nifedipine therapy. Wilcoxon's signed ranks test was used to analyze the difference between the two variables. A P-value of < 0.05 was considered significant.Results: The result of the study showed nifedipine was associated with a significant decreased of pulsatility index uterine artery (p = 0.016; p-value<0.05) and umbilical artery (p = 0.037; p-value<0.05) after 48 hours therapy, while pulsatility index of fetal middle cerebral arteries, ductus venosus, and cerebroplacental ratio did not change significantly.Conclusion: The study concluded that nifedipine as tocolytic increased blood flow of uterine artery and umbilical artery after 48 hours therapy.
Meneliti perbedaan karakteristik umur, paritas, besar uterus, kadar β-hCG, dan hiperproliferasi pada mola hidatidosa (MH) dengan regresi spontan dan pada MH dengan transformasi keganasan di RS Dr. Hasan Sadikin Bandung. Metode: Penelitian cross sectional deskriptif restrospektif mengambil data umur, paritas, besar uterus, kadar β-hCG pre-evakuasi, dan hiperproliferasi dari rekam medis pasien MH periode 2007-2016. Data diolah menggunakan program SPSS versi 20.0 for Windows. Nilai p<0,05 dianggap signifikan. Hasil: Dari 400 rekam medis yang dianalisis, 233 dengan data lengkap dapat dianalisis. Mayoritas pasien usia reproduktif 20-35(53,6%) tahun, paritas 1-2 (n=90, 38,6%), dan besar uterus rata-rata 19,12±4,633 (~minggu kehamilan). Kadar β-hCG <100000 mIU/mL sebanyak 78(33,5%), ≥100000 mIU/mL sebanyak 155(66,5%). Pasien dengan hiperproliferasi sebanyak 83(35,6%) sedangkan pasien tanpa hiperproliferasi sebanyak 150(64,4%). Terdapat 219(94,0%) dengan komplit MH, dan 14(6,0%) HM parsial (tidak dipublikasi). Pasien kemudian dikategorikan menjadi kelompok transformasi keganasan dan kelompok remisi spontan. Tidak terdapat perbedaan umur, paritas, dan besar uterus diantara dua kelompok (p>0,05). Perbedaan kadar βhCG (mIU/mL) dan tingkat proliferasi menunjukkan hasil signifikan (p<0.05). Kesimpulan: Kadar β-hCG preevakuasi dan status hiperproliferasi dapat digunakan sebagai prediktor transformasi keganasan pasien MH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.